Immunogenicity and safety of live attenuated hepatitis A vaccine: a multicentric study.

Simple item page
dc.contributor.authorFaridi, M M Aen_US
dc.contributor.authorShah, Nitinen_US
dc.contributor.authorGhosh, T Ken_US
dc.contributor.authorSankaranarayanan, V Sen_US
dc.contributor.authorArankalle, Vidyaen_US
dc.contributor.authorAggarwal, Anjuen_US
dc.contributor.authorSathiyasekaran, Malathien_US
dc.contributor.authorBhattacharya, Nishaen_US
dc.contributor.authorVasanthi, Ten_US
dc.contributor.authorChatterjee, Suparnaen_US
dc.contributor.authorChoudhury, Jaydeepen_US
dc.contributor.authorMitra, Monjorien_US
dc.date.accessioned2009-01-31en_US
dc.date.accessioned2009-05-27T05:54:11Z
dc.date.available2009-01-31en_US
dc.date.available2009-05-27T05:54:11Z
dc.date.issued2009-01-31en_US
dc.description.abstractOBJECTIVE: To evaluate immunogenicity and tolerability of single dose live attenuated injectable hepatitis A vaccine in four metropolitan cities of India. METHODS: Live attenuated hepatitis A vaccine was administered to 505 children aged 18 to 60 months in four centers across India. Immunogenicity of the vaccine was assessed by estimation of anti-HAV antibody titer at 6 weeks and 6 months following administration of the vaccine. Safety evaluation of the vaccine was also done during the visits. RESULTS: At 6 weeks, 480 subjects (95%) came for the follow-up and 411 (81.4%) subjects reported at the end of 6 months. The geometric mean titer (GMT) of anti-HAV antibody of the subjects who did not have the seroprotective titer at the baseline were assessed at 6 weeks and 6 months which was 81.04 mIU/ml and 150.66 mIU/ml respectively. At 6 weeks, 95.1 % seroconverted and at the end of 6 months, 97.9 % had seroconverted. Both solicited and unsolicited vaccine-induced local and systemic adverse events were insignificant at all the centers, except swelling and induration in a few. CONCLUSION: Live attenuated injectable hepatitis A vaccine was immunogenic and tolerable with minimal reactogenecity, in this study of single dose schedule. Safety profile was also satisfactory in the study population.en_US
dc.description.affiliationDepartment of Pediatrics, University College of Medical Sciences, New Delhi.en_US
dc.identifier.citationFaridi MM, Shah N, Ghosh TK, Sankaranarayanan VS, Arankalle V, Aggarwal A, Sathiyasekaran M, Bhattacharya N, Vasanthi T, Chatterjee S, Choudhury J, Mitra M. Immunogenicity and safety of live attenuated hepatitis A vaccine: a multicentric study. Indian Pediatrics. 2009 Jan; 46(1): 29-34en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/13823
dc.language.isoengen_US
dc.source.urihttps://indianpediatrics.neten_US
dc.subject.meshChild, Preschoolen_US
dc.subject.meshFemaleen_US
dc.subject.meshHepatitis A --prevention & controlen_US
dc.subject.meshHepatitis A Antibodies --analysisen_US
dc.subject.meshHepatitis A Vaccines --administration & dosageen_US
dc.subject.meshHumansen_US
dc.subject.meshImmunoassayen_US
dc.subject.meshInfanten_US
dc.subject.meshMaleen_US
dc.titleImmunogenicity and safety of live attenuated hepatitis A vaccine: a multicentric study.en_US
dc.typeJournal Articleen_US
dc.typeMulticenter Studyen_US
dc.typeResearch Support, Non-U.S. Gov'ten_US
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.79 KB
Format:
Plain Text
Description:
Download
Collections
Indian Pediatrics